AI adopters trade gaining steam; top stocks in AI adoption sectors
Seeking Alpha News (Tue, 9-Dec 4:28 AM ET)
Market Chameleon (Mon, 8-Dec 3:49 AM ET)
PRNewswire (Sat, 6-Dec 10:40 PM ET)
Safusidenib Shows 44% Response Rate and Long-Term Disease Control in Nuvation Bio Phase 2 Study
Market Chameleon (Wed, 3-Dec 3:35 AM ET)
Business Wire (Wed, 3-Dec 8:00 AM ET)
Nuvation Bio to Participate in Upcoming Investor Conferences
Business Wire (Wed, 26-Nov 4:05 PM ET)
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Business Wire (Mon, 3-Nov 4:05 PM ET)
Business Wire (Thu, 23-Oct 7:30 AM ET)
Business Wire (Mon, 20-Oct 4:05 PM ET)
NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street
PRNewswire (Wed, 8-Oct 8:55 AM ET)
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Nuvation Bio Class A trades on the NYSE stock market under the symbol NUVB.
As of December 9, 2025, NUVB stock price declined to $8.00 with 4,483,436 million shares trading.
NUVB has a beta of 1.31, meaning it tends to be more sensitive to market movements. NUVB has a correlation of 0.06 to the broad based SPY ETF.
NUVB has a market cap of $2.74 billion. This is considered a Mid Cap stock.
Last quarter Nuvation Bio Class A reported $13 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $6 million and met earnings estimates .
In the last 3 years, NUVB traded as high as $8.95 and as low as $.95.
The top ETF exchange traded funds that NUVB belongs to (by Net Assets): IWM, VTI, IWN, IBB, VXF.
NUVB has outperformed the market in the last year with a price return of +180.7% while the SPY ETF gained +13.6%. NUVB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +129.2% and +8.0%, respectively, while the SPY returned +5.6% and +2.1%, respectively.
NUVB support price is $8.07 and resistance is $9.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUVB shares will trade within this expected range on the day.
